World views China better than US, poll finds

Median approval: 36% for China vs 31% for the US across >130 countries per a 2025 Gallup poll. US global approval slid from 39% to 31% between 2024 and 2025 (an 8 percentage-point drop), with the largest decline in Germany (-39 percentage points); Israeli views of the US improved. Poll predates or does not account for recent US foreign-policy actions (raid capturing Nicolás Maduro, Iran war), which could alter perceptions.

Analysis

A persistent edge in global approval for Beijing versus Washington is not just a PR metric — it lowers transaction costs for Chinese diplomacy and commercial expansion in markets where perception matters (Africa, Latin America, parts of SE Asia). Expect faster conversion of soft power into concessional financing, preferential infrastructure deals, and preferential procurement for Chinese firms over Western peers in 6–36 months, especially where political optics trump strict due diligence.

Second-order corporate effects will show up unevenly: multinational supply chains tied to export-oriented EMs may tilt toward Chinese-led procurement consortia (equipment, telecom, construction), reducing European and US OEMs’ share in those tenders; conversely, US defense and security firms should see short-term revenue uplifts as allies hedge perceived reduction in US influence by increasing defense spending or diversifying suppliers. Currency and funding channels matter — greater Chinese approval lowers political risk premia on RMB-denominated financing in targeted EMs, widening the funding gap versus dollar sources over the next 12–24 months.

Near-term reversals are plausible: high-profile, successful US kinetic/diplomatic actions or a visible de-escalation in hot spots could restore credibility quickly (days–weeks). Structural reversal requires sustained policy shifts from Washington (rebuilt alliance management + finance) or a Chinese policy misstep (credit event, diplomatic overreach) over 6–24 months. For investors, the main lever is not “China vs US” as abstraction but where that perception changes procurement, funding, and capital allocation decisions — those are the pockets of alpha to target and hedge around.

Key Decisions for Investors

• Tactical long China large-caps: Buy FXI (iShares China Large-Cap ETF) on a 3–12 month horizon to capture re-rating if Chinese soft power translates into higher capital flows and domestic policy support. Target +20–30% upside if sentiment-driven multiple expansion resumes; set a 15% stop to limit regulatory/event tail risk.
• Emerging markets tilt: Add EEM (iShares MSCI Emerging Markets ETF) overweight for 6–18 months to play spillover benefits from increased Chinese financing and trade with EMs. Reward: 15–25% potential if reallocations accelerate; risks: US rates and China growth shocks — hedge duration exposure with a 2–3% allocation to short-duration Treasuries.
• Defense hedge: Long LMT (Lockheed Martin) or RTX (RTX Corp) on a 0–12 month horizon to protect portfolios from episodic escalation and allied re-armament. Expect 8–18% upside in an elevated-risk regime; cap position sizes and take profits if headline-driven volatility normalizes.
• Relative-value pair: Go long FXI / short SPY as a thematic 6–12 month pair trade sized to 1–2% net portfolio risk to express the China sentiment spread vs US. If China’s approval converts into capital flows and procurement wins, expect asymmetric upside in FXI; failure or US diplomatic wins would favor SPY — use a 10–12% trailing stop on the FXI leg.